Division of Anatomy Pathology and Cytopathology, Tawam Hospital, Al Ain, United Arab Emirates,
Education Institute, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Acta Cytol. 2021;65(3):205-212. doi: 10.1159/000513066. Epub 2021 Feb 1.
Atypia/follicular lesion of undetermined significance (AUS/FLUS) carries a malignancy risk reaching up to 50%. Based on the reported malignancy rate in a given population, the clinical practice towards such a category varies. We hereby identify clinical parameters for risk stratification to aid in decision-making for either surgical referral or a clinical follow-up. Our aim is to identify clinical parameters that guided both clinicians and patients at our institutions to reach a clinical decision including atypia types.
A retrospective review of patients with Bethesda III category thyroid nodules from tertiary centres in the Emirate of Abu Dhabi during January 2011 through December 2015 was carried out. Malignancy risk in Bethesda category III nodules and repeat FNA utility were calculated. Parameters that guided both clinicians and patients for appropriate referral to surgery were studied.
Two hundred and two cases were included in the study. Of these, 101 cases underwent surgery initially following the first FNA and 10 cases following FNA repeat. Histology confirmed malignancy in (41%) of cases that went initially to surgery and in (40%) of cases that underwent a repeat FNA. Repeat FNA resulted in 17 (44.74%) cases being re-classified into benign category, 10 (26.3%) being AUS/FLUS category, 6 (15.7%) being both suspicious and malignant, and 5 (13.16%) being unsatisfactory. Repeating FNA resulted in a definitive diagnostic utility in 50% of the cases. Eighty percent of malignant cases demonstrated nuclear atypia.
The relatively high malignancy rate in our institutions, the suspicious radiographic features, the atypia groups, and the repeat FNA predictive value stratified Bethesda III category nodules for proper malignancy prediction and appropriate management.
不典型/滤泡性病变意义未明(AUS/FLUS)的恶变风险高达 50%。基于特定人群中的报告恶变率,对这一类别采取的临床处理方法存在差异。我们在此确定风险分层的临床参数,以帮助决策是进行手术转诊还是临床随访。我们的目的是确定临床参数,以便为临床医生和患者提供指导,帮助他们在我们的机构中做出临床决策,包括不典型类型。
对 2011 年 1 月至 2015 年 12 月阿布扎比酋长国的三家三级中心的 Bethesda Ⅲ类甲状腺结节患者进行了回顾性研究。计算了 Bethesda Ⅲ类结节的恶变风险和重复细针抽吸活检(FNA)的效用。研究了指导临床医生和患者进行适当转诊手术的参数。
本研究共纳入 202 例患者。其中 101 例在首次 FNA 后立即手术,10 例在重复 FNA 后手术。组织学证实,初次手术的 41%病例和重复 FNA 的 40%病例存在恶性肿瘤。重复 FNA 导致 17 例(44.74%)病例重新分类为良性,10 例(26.3%)为 AUS/FLUS 类别,6 例(15.7%)为可疑恶性和恶性,5 例(13.16%)为不满意。重复 FNA 对 50%的病例具有明确的诊断效用。80%的恶性病例表现为核异型性。
我们机构中的恶变率相对较高、可疑的影像学特征、不典型组以及重复 FNA 的预测值,对 Bethesda Ⅲ类结节进行了分层,以进行适当的恶变预测和管理。